Skip to Content

Janumet Approval History

FDA Approved: Yes (First approved March 30, 2007)
Brand name: Janumet
Generic name: metformin and sitagliptin
Dosage form: Tablets
Company: Merck & Co., Inc.
Treatment for: Diabetes, Type 2

Janumet is a combination of the oral antihyperglycemic drugs sitagliptin and metformin indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Development History and FDA Approval Process for Janumet

DateArticle
Feb  2, 2012Approval FDA Approves Janumet XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of Janumet (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
Apr  2, 2007Approval FDA Approves Janumet for Type 2 Diabetes, Offering Powerful GlucoseControl of a DPP-4 Inhibitor and Metformin in a Single Tablet
Dec  1, 2006Merck Announces Janumet, the Trademark for its Investigational Combination Therapy of Sitagliptin Phosphate and Metformin for Type 2 Diabetes
Jul 31, 2006Merck Announces FDA Acceptance of NDA for MK-0431A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide